maytansine and Carcinoma--Small-Cell

maytansine has been researched along with Carcinoma--Small-Cell* in 2 studies

Trials

1 trial(s) available for maytansine and Carcinoma--Small-Cell

Article	Year
Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578). Cancer treatment reports, 1982, Volume: 66, Issue:6 Seventy-three patients with small cell lung carcinoma refractory to standard chemotherapy were entered in this phase II randomized study of cisplatin, maytansine, and chlorozotocin. Of the 58 evaluable patients, only one partial response was observed among 21 patients given cisplatin, and no responses were seen among 19 given maytansine or 18 given chlorozotocin. One patient treated with chlorozotocin and two treated with cisplatin experienced life-threatening thrombocytopenia. One third of the maytansine-treated patients experienced moderate or severe neurologic toxicity. The overall median survival was 9.7 weeks. Chlorozotocin treatment was associated with inferior survival (7.7 weeks). Topics: Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Maytansine; Middle Aged; Streptozocin	1982

Article

Year

Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578).

Cancer treatment reports, 1982, Volume: 66, Issue:6

Seventy-three patients with small cell lung carcinoma refractory to standard chemotherapy were entered in this phase II randomized study of cisplatin, maytansine, and chlorozotocin. Of the 58 evaluable patients, only one partial response was observed among 21 patients given cisplatin, and no responses were seen among 19 given maytansine or 18 given chlorozotocin. One patient treated with chlorozotocin and two treated with cisplatin experienced life-threatening thrombocytopenia. One third of the maytansine-treated patients experienced moderate or severe neurologic toxicity. The overall median survival was 9.7 weeks. Chlorozotocin treatment was associated with inferior survival (7.7 weeks).

Topics: Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Maytansine; Middle Aged; Streptozocin

1982

Other Studies

1 other study(ies) available for maytansine and Carcinoma--Small-Cell

Article	Year
Technology evaluation: huN901-DM1, ImmunoGen. Current opinion in molecular therapeutics, 2005, Volume: 7, Issue:4 ImmunoGen is developing huN901-DMI, a compound comprised of a CD56-targeted humanized N901 antibody conjugated to the company's proprietary cytotoxic agent. DM1, using its tumor-activated prodrug technology, for the potential treatment of cancers that express CD56, in particular, small-cell lung cancer. Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Small Cell; CD56 Antigen; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Maytansine; Prodrugs; Trastuzumab	2005

Article

Year

Technology evaluation: huN901-DM1, ImmunoGen.

Current opinion in molecular therapeutics, 2005, Volume: 7, Issue:4

ImmunoGen is developing huN901-DMI, a compound comprised of a CD56-targeted humanized N901 antibody conjugated to the company's proprietary cytotoxic agent. DM1, using its tumor-activated prodrug technology, for the potential treatment of cancers that express CD56, in particular, small-cell lung cancer.

Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Small Cell; CD56 Antigen; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Maytansine; Prodrugs; Trastuzumab

2005